Rheumatology Landing Page


Deadline Extended to March 17, 2016!


**Please note that the online application portal will not be available from 12:00pm EST Friday March 11 through 9:00am EST
Monday March 14.


2016 ASPIRE Rheumatology, Dermatology and Inflammatory Bowel Disease Research Awards

This ASPIRE program is part of Pfizer's commitment to supporting research in autoimmune diseases within rheumatology, dermatology and inflammatory bowel disease.

Mission

The mission of the ASPIRE program is to fund high quality basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases.

Background

Scientific research continues to advance our knowledge and understanding of autoimmune diseases within rheumatology, dermatology and inflammatory bowel disease. The 2016 ASPIRE Rheumatology, Dermatology and Inflammatory Bowel Disease Research Awards will fund meritorious research proposals that have the potential to improve patient care.

Areas of Focus

Research areas of interest in rheumatoid arthritis, dermatology and inflammatory bowel disease are as follows:

General

  • Approaches to improving communication among patients and healthcare providers (e.g., enduring materials, technological advancements, or web-based teaching programs)
  • Health economic and outcomes research related to autoimmune diseases
  • Basic research in the etiology of autoimmune and inflammatory diseases in rheumatology, dermatology or gastroenterology.

Rheumatoid Arthritis

  • Use of biomarkers, ultrasound and magnetic resonance imaging (MRI) in assessment and management of RA
  • Comorbid conditions such as cardiovascular risk, ophthalmologic risk, risk of diabetes, interstitial lung diseases, increased risks with concomitant therapies (epidemiology, overlapping pathogenesis, assessment, and management of these conditions)
  • Approaches to improving adherence to therapy
  • Approaches to improving management such as: treating to a specific goal or target by monitoring response and adjusting therapy; evidence-based treatment algorithms; factors predictive of response to therapy
  • Signaling pathways implicated in pathogenesis
  • Kinase inhibitors and other small molecules that are not being studied currently by a company competing with Pfizer Inc.

Dermatology

  • Genomic research to improve understanding of the heterogeneity of inflammatory and immune-mediated skin conditions (e.g., differences between “early” onset and “late” onset)
  • Signaling pathways implicated in the pathogenesis of inflammatory or immune-mediated skin conditions
  • Use of clinical tools to evaluate the severity of inflammatory or immune-mediated skin conditions or the impact of these conditions of patient quality of life
  • Approaches to improving adherence to therapy’
  • Approaches to improving management (e.g., treating to a specific goal or target, treatment algorithms)
  • Research related to, but not limited to, the use of kinase inhibitors in the treatment of inflammatory or immune-mediated skin disorders with an unmet therapeutic need

Inflammatory bowel disease

  • Exploration of the role of JAK/STAT pathways in pathogenesis of inflammatory bowel disease
  • Use of biomarkers (of any type) to predict response to treatment, disease course, or to differentiate between Crohn's disease and ulcerative colitis
  • Approaches to improving disease management (e.g. evaluation of sequencing of therapy, treating to a specific goal or target)
  • Approaches to improving adherence to therapy

Available Awards

ASPIRE Rheumatology, Dermatology and Inflammatory Bowel Disease research awards are up to a maximum of $150,000 each. Research projects are expected to complete within 2 years of study start. Larger grants may be considered depending on scope and merit of proposal.